Cocrystal Pharma, Inc. (COCP) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Cocrystal Pharma reported revenue of $0. Net income was -$8.8M, or -$0.78 per diluted share. Operating activities generated -$8.2M of cash, leaving -$8.2M of free cash flow. At fiscal year end, Cocrystal Pharma held $9.7M in total assets against $3.4M in total liabilities, including $7.0M of cash and equivalents.
Open the full interactive Cocrystal Pharma financials → Quarterly statements, key ratios, valuation history and price charts.
Cocrystal Pharma Key Stats
| Share Price | $1.08 |
|---|---|
| Market Cap | $14.9M |
| 52-Week Range | $0.82 – $1.57 |
| Shares Outstanding | 13.8 million (basic, 2026 Q2) |
Cocrystal Pharma Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $2.0M | — | $0 | $0 | $0 | $0 |
| Operating Income | -$9.6M | -$14.2M | -$38.8M | -$18.6M | -$17.9M | -$9.0M |
| Pre-Tax Income | -$9.6M | -$14.2M | -$38.8M | -$18.0M | -$17.5M | -$8.8M |
| Net Income | -$9.6M | -$14.2M | -$38.8M | -$18.0M | -$17.5M | -$8.8M |
| Diluted EPS | -$2.04 | -$1.92 | — | -$1.87 | -$1.72 | -$0.78 |
Cocrystal Pharma Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $225,000 | $105,000 |
| Net Income | -$2.0M | -$2.4M | -$2.3M | -$3.2M |
| Diluted EPS | -$0.19 | -$0.21 | -$0.17 | -$0.23 |
Cocrystal Pharma Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $33.0M | $58.7M | $37.2M | $26.4M | $9.9M | $7.0M |
| Current Assets | $34.0M | $59.3M | $40.2M | $29.1M | $11.6M | $8.1M |
| Total Assets | $54.2M | $79.4M | $40.8M | $31.3M | $13.5M | $9.7M |
| Current Liabilities | $1.4M | $1.5M | $1.2M | $3.3M | $2.4M | $2.2M |
| Total Liabilities | $1.7M | $1.8M | $1.3M | $4.9M | $3.9M | $3.4M |
| Shareholders' Equity | $52.5M | $77.5M | $39.6M | $26.4M | $9.5M | $6.3M |
Cocrystal Pharma Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$9.8M | -$12.7M | -$21.4M | -$14.7M | -$16.5M | -$8.2M |
| Cash From Investing | -$240,000 | -$52,000 | -$74,000 | -$118,000 | -$8,000 | -$12,000 |
| Cash From Financing | $35.7M | $38.5M | -$27,000 | $4.0M | — | $5.4M |
| Free Cash Flow | -$10.1M | -$12.8M | -$21.5M | -$14.8M | -$16.5M | -$8.2M |
Figures from Cocrystal Pharma's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Cocrystal Pharma financials page for every line item.
Cocrystal Pharma Company Profile
| Ticker | COCP |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Bothell, Washington |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001412486 |
Frequently Asked Questions
What was Cocrystal Pharma's revenue in fiscal 2025?
Cocrystal Pharma (COCP) reported revenue of $0 for fiscal 2025.
What is Cocrystal Pharma's annual revenue history?
Cocrystal Pharma's annual revenue by fiscal year: 2020: $2.0M; 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was Cocrystal Pharma's net income in fiscal 2025?
Cocrystal Pharma reported net income of -$8.8M for fiscal 2025.
What was Cocrystal Pharma's earnings per share (EPS) in fiscal 2025?
Cocrystal Pharma's diluted EPS was -$0.78 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Cocrystal Pharma generate in fiscal 2025?
Cocrystal Pharma generated -$8.2M of free cash flow in fiscal 2025.
What was Cocrystal Pharma's revenue last quarter?
In its most recent reported quarter (2026 Q2), Cocrystal Pharma reported revenue of $105,000.
How many shares of Cocrystal Pharma are outstanding?
Cocrystal Pharma reported a weighted average of 13.8 million basic shares outstanding in 2026 Q2.
What is Cocrystal Pharma's market cap?
Based on its latest closing price, Cocrystal Pharma (COCP) has a market capitalization of about $14.9M.
When does Cocrystal Pharma's fiscal year end?
Cocrystal Pharma's fiscal year end, as registered with the SEC, is December 31.
Where is Cocrystal Pharma headquartered?
Cocrystal Pharma lists its business address in Bothell, Washington in its SEC filings.